MDNA News and Press, Medicenna Therapeutics Corp. From 10/01/21

The following slide deck was published by Medicenna Therapeutics Corp. in conjunction with this event. For further details see: Medicenna Therapeutics (MDNA) Next-Gen Cytokine Therapeutics Summit Presentation - Slideshow

TORONTO and HOUSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of John H. Sampson, MD, PhD, MBA, to its Board ...

TORONTO and HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Nex...

TORONTO and HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that the US Patent and Trademark Office (USPTO) has issued U.S....

-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Preliminary efficacy readout...

TORONTO and HOUSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of th...

Medicenna Therapeutics Corp. (MDNA) Q1 2022 Earnings Conference Call August 13, 2021 08:30 AM ET Company Participants Dan Ferry - Managing Director-LifeSci Advisors Fahar Merchant - President & Chief Executive Officer Mann Muhsin - Chief Medical Officer Liz Williams - Chief Financial Offi...

-- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 -- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Me...

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET...

koto_feja/E+ via Getty Images Medicenna Therapeutics (MDNA) said that the initiation of its Phase 1/2 trial of MDNA11 in patients with advanced solid tumors is on track with enrollment set to start in the third quarter of 2021 in Australia. Shares up nearly 9% premark...